Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

However, the vaccine manufacturers concerned may appeal against this decision in order to protect their professional, commercial and manufacturing secrets, the Federal Office of P ...

BioNTech (BNTX) stock tumbles 17% after reporting Q4 losses, missing 2026 revenue projections, and announcing co-founder departures. Full analysis here.

There's no easy way to identify the most hated stocks on Wall Street, but looking at the activity of short sellers is a great place to start. Short selling is a difficult art that involves ...

The German biotech provides a weak full-year outlook and announces the exit of its co-founders.

BioNTech (NASDAQ:BNTX) management outlined a strategy centered on late-stage oncology execution and combination-based development during the company’s fourth-quarter and full-year 2025 earnings call, ...